vs
Side-by-side financial comparison of MicroAlgo Inc. (MLGO) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
MicroAlgo Inc. is the larger business by last-quarter revenue ($26.3M vs $19.1M, roughly 1.4× NewAmsterdam Pharma Co N.V.). On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -35.5%).
MicroAlgo Inc. is a technology enterprise specializing in custom algorithm optimization solutions. It mainly serves clients across smart city management, industrial internet, and e-commerce sectors, helping enterprises improve operational efficiency, reduce operating costs, and optimize data processing performance for real business scenarios.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
MLGO vs NAMS — Head-to-Head
Income Statement — Q2 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.3M | $19.1M |
| Net Profit | — | $-17.4M |
| Gross Margin | — | — |
| Operating Margin | — | -186.1% |
| Net Margin | — | -90.7% |
| Revenue YoY | -35.5% | 740.1% |
| Net Profit YoY | — | 55.5% |
| EPS (diluted) | — | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $26.3M | $19.1M | ||
| Q4 24 | $34.6M | $12.8M | ||
| Q3 24 | — | $29.1M | ||
| Q2 24 | $40.8M | — | ||
| Q2 23 | $20.2M | $8.6M | ||
| Q1 23 | $17.8M | — | ||
| Q2 22 | $28.2M | — | ||
| Q1 22 | $23.4M | — |
| Q2 25 | — | $-17.4M | ||
| Q4 24 | $4.2M | $-92.2M | ||
| Q3 24 | — | $-16.6M | ||
| Q2 24 | — | — | ||
| Q2 23 | $-4.8M | $-42.0M | ||
| Q1 23 | $-1.3M | — | ||
| Q2 22 | $-23.6K | — | ||
| Q1 22 | $888.4K | — |
| Q2 25 | — | — | ||
| Q4 24 | 26.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | 33.0% | — | ||
| Q1 23 | 27.8% | — | ||
| Q2 22 | -0.1% | — | ||
| Q1 22 | 23.1% | — |
| Q2 25 | — | -186.1% | ||
| Q4 24 | 7.0% | -338.5% | ||
| Q3 24 | — | -85.9% | ||
| Q2 24 | — | — | ||
| Q2 23 | -7.7% | -461.8% | ||
| Q1 23 | -7.9% | — | ||
| Q2 22 | -0.1% | — | ||
| Q1 22 | 5.0% | — |
| Q2 25 | — | -90.7% | ||
| Q4 24 | 12.1% | -721.7% | ||
| Q3 24 | — | -57.2% | ||
| Q2 24 | — | — | ||
| Q2 23 | -23.7% | -486.9% | ||
| Q1 23 | -7.1% | — | ||
| Q2 22 | -0.1% | — | ||
| Q1 22 | 3.8% | — |
| Q2 25 | — | $-0.15 | ||
| Q4 24 | $0.56 | $-0.91 | ||
| Q3 24 | — | $-0.18 | ||
| Q2 24 | — | — | ||
| Q2 23 | — | $-0.51 | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $319.4M | $739.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $317.6M | $778.5M |
| Total Assets | $330.8M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $319.4M | $739.2M | ||
| Q4 24 | $164.9M | $834.2M | ||
| Q3 24 | — | $422.7M | ||
| Q2 24 | $66.7M | — | ||
| Q2 23 | $19.2M | — | ||
| Q1 23 | $21.0M | — | ||
| Q2 22 | $10.9K | — | ||
| Q1 22 | $28.7K | — |
| Q2 25 | $317.6M | $778.5M | ||
| Q4 24 | $144.9M | $757.5M | ||
| Q3 24 | — | $378.9M | ||
| Q2 24 | $76.0M | — | ||
| Q2 23 | $60.4M | $398.4M | ||
| Q1 23 | $66.7M | — | ||
| Q2 22 | $-3.0M | — | ||
| Q1 22 | $-2.5M | — |
| Q2 25 | $330.8M | $815.1M | ||
| Q4 24 | $176.3M | $864.6M | ||
| Q3 24 | — | $439.2M | ||
| Q2 24 | $107.6M | — | ||
| Q2 23 | $71.8M | — | ||
| Q1 23 | $75.6M | — | ||
| Q2 22 | $47.3M | — | ||
| Q1 22 | $46.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-37.7M |
| Free Cash FlowOCF − Capex | — | $-37.8M |
| FCF MarginFCF / Revenue | — | -197.2% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-37.7M | ||
| Q4 24 | $4.8M | $-37.5M | ||
| Q3 24 | — | $-12.5M | ||
| Q2 24 | — | — | ||
| Q2 23 | $-3.8M | $-31.9M | ||
| Q1 23 | $-2.8M | — | ||
| Q2 22 | $-747.8K | — | ||
| Q1 22 | $456.6K | — |
| Q2 25 | — | $-37.8M | ||
| Q4 24 | $4.8M | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q2 24 | — | — | ||
| Q2 23 | — | $-31.9M | ||
| Q1 23 | $-2.8M | — | ||
| Q2 22 | — | — | ||
| Q1 22 | $270.9K | — |
| Q2 25 | — | -197.2% | ||
| Q4 24 | 13.8% | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q2 24 | — | — | ||
| Q2 23 | — | -369.3% | ||
| Q1 23 | -15.8% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | 1.2% | — |
| Q2 25 | — | 0.5% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | 0.0% | — | ||
| Q2 23 | — | 0.1% | ||
| Q1 23 | 0.3% | — | ||
| Q2 22 | — | — | ||
| Q1 22 | 0.8% | — |
| Q2 25 | — | — | ||
| Q4 24 | 1.15× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q2 22 | — | — | ||
| Q1 22 | 0.51× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
